Gilead HIV Drug Lawsuit: The TDF Kidney and Bone Claims

What the Lawsuits Allege

Gilead Sciences makes widely used HIV medications built on tenofovir. The lawsuits focus on the older form, tenofovir disoproxil fumarate (TDF), found in drugs like Viread, Truvada, Atripla and Complera. Plaintiffs allege that TDF, while effective against HIV, can cause serious kidney problems (including chronic kidney disease and kidney failure) and bone loss (demineralization, osteoporosis and fractures). Critically, they allege Gilead knew a newer, gentler version — tenofovir alafenamide (TAF) — was safer for the kidneys and bones, but delayed bringing it to market to maximize profits from the older drug first.

The claim is not that the drugs failed to treat HIV, but that patients suffered avoidable harm and were not adequately warned while a safer option was held back.

The Litigation and Settlement

In June 2024, Gilead agreed to a $40 million settlement resolving roughly 2,600 claims in federal court, describing it as a way to avoid the cost of litigating rather than an admission of wrongdoing. That deal, however, left a much larger body of cases unresolved: tens of thousands of TDF lawsuits remain pending, largely in California state court, where the litigation continues. So this is best understood as a partial, early resolution in a much bigger fight.

Because the science of who was harmed and how turns on individual medical histories, these cases are contested and fact-specific.

What Patients Should Know

HIV medication is life-saving, and no one should stop treatment based on litigation — modern regimens, including TAF-based drugs, are highly effective. If you took a TDF-based drug and developed kidney disease or significant bone loss, discuss it with your doctor and keep your medical and prescription records. As always, be cautious of advertising that presents a payout as guaranteed in litigation that is still being fought.